Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01181479 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System
A Phase 3 study, sponsored by Agile Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,504
- Enrollment target
NCT01181479: Completed Phase 3 study, sponsored by Agile Therapeutics.
NCT01181479 is a Phase 3 study that has completed, run by Agile Therapeutics. The registered enrollment target is 1,504 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01181479, a Phase 3 study, has completed, sponsored by Agile Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,504 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.
Primary Outcome
Pregnancy outcomes was determine by measuring Pearl index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.
Interventions
- DRUG AG200-15 (cycles 1-13)
- DRUG Lessina crossover to AG200-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,504 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
What the finished NCT01181479 record still lists
NCT01181479 is an interventional study that assigns participants to a tested intervention. Its 1,504 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 2 interventions - of which AG200-15 (cycles 1-13) is the first listed.
NCT01181479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01181479 about?
NCT01181479 is a clinical study titled "Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System". The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.
What is the current status of trial NCT01181479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,504 participants. The study started on 2010-08. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01181479?
The interventions under investigation include: AG200-15 (cycles 1-13) (DRUG), Lessina crossover to AG200-15 (DRUG).
Who is sponsoring clinical trial NCT01181479?
This trial is sponsored by Agile Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01181479's enrollment target sits among peer trials
1,504 157th of 2000 higher than 1,844 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia